Valeant Architect Bets On Drugmaker by Returning to the BoardBy and
ValueAct's Mason Morfit rejoins company he helped shape
SEC rules likely prevent ValueAct from adding shares for now
ValueAct Capital Management helped make Valeant Pharmaceuticals International Inc. what it is today -- and now the activist fund is stepping up to defend its creation.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.